Global Renal Biomarkers Market Size study & Forecast, by Biomarker type (Functional Biomarker, Up-regulated Protein, and Other Biomarker Types) by Diagnostic Technique ((Enzyme-linked Immunosorbent Assay, Particle-enhanced Turbidimetric Immunoassay (PETIA

Global Renal Biomarkers Market Size study & Forecast, by Biomarker type (Functional Biomarker, Up-regulated Protein, and Other Biomarker Types) by Diagnostic Technique ((Enzyme-linked Immunosorbent Assay, Particle-enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), and Liquid Chromatography-mass Spectrometry (LS-MS)), by End User (Hospitals, Diagnostic Laboratories, and Other End Users) and Regional Analysis, 2022-2029

Global Renal Biomarkers Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. A biomarker is a biological characteristic of an organism that is assessed as a sign of typical biological function. Renal biomarkers are a crucial diagnostic tool for identifying both acute and chronic kidney injury as well as several other kidney disorders. Renal disorders are primarily treated using renal biomarkers. These biomarkers are helpful in both research and clinical contexts and are used to analyze the renal system's functionality. The Renal Biomarkers Market is expanding because of factors such as the increasing incidence of various kidney-related diseases, and the increasing rate of progression of chronic kidney disease.

A Kidney International Supplements article from April 2022 claims that millions of people worldwide pass away each year from chronic kidney disease, which affects about 10% of the world's population. Chronic renal disease individuals are becoming more prevalent. Also, compared to Western nations, Asian nations had a significantly higher incidence of diabetes-related chronic renal illnesses. For instance, according to a 2021 report from the International Diabetes Federation, India had an estimated 74,194.7 thousand cases of diabetes in 2021, and by 2030, that number is predicted to rise to 92,973.7 thousand cases. Thus, it is anticipated that over the projection period, demand for renal disease diagnosis would rise in response to the rising prevalence of kidney illnesses and their associated causes. This will fuel the development of biomarkers. Furthermore, advancements in the field of genetic technology strategic activities by market players for product development are creating lucrative growth in the market. However, the high cost of renal biomarkers may halt market growth.

The key regions considered for the Global Renal Biomarkers Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of branded products and the region's increasing disease prevalence. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:
Abbott Laboratories
BioPorto Diagnostics AS
F. Hoffmann-La Roche AG
Thermo Fisher Scientific Inc.
Nexelis (Pacific Biomarkers)
BioMérieux
Sphingotec GmbH
Randox Laboratories Ltd
Siemens Healthineers AG
Enzo Life Sciences, Inc.

Recent Developments in the Market:
 In December 2022, the company Journey Biosciences, Inc. has announced the release of NaviDKD, its flagship product, a blood test based on biomarkers that forecast long-term kidney issues in diabetics. The only screening method that gives diabetics a head starts on the risk of developing kidney disease.
 In March 2022, Renalytix plc has announced the launch of myIntelX, a new provider access portal that will enable doctors to order KidneyIntelX prognostic (blood-based biomarker) testing online for more accurate identification of patients at the highest risk of rapid progression of kidney disease in type 2 diabetes.




Global Renal Biomarkers Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Biomarker type, Diagnostic Technique, End User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Biomarker typeofferings of key players. The detailed segments and sub-segment of the market are explained below:

By Biomarker Type:
Functional Biomarker
Up-regulated Protein
Other Biomarker Types

By Diagnostic Technique:
Enzyme-linked Immunosorbent Assay
Particle-enhanced Turbidimetric Immunoassay (PETIA)
Colorimetric Assay
Chemiluminescent Enzyme Immunoassay (CLIA)
Liquid Chromatography-mass Spectrometry (LS-MS)

By End User:
Hospitals
Diagnostic Laboratories
Other End Users

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned
Abbott Laboratories
BioPorto Diagnostics AS
F. Hoffmann-La Roche AG
Thermo Fisher Scientific Inc.
Nexelis (Pacific Biomarkers)
BioMérieux
Sphingotec GmbH
Randox Laboratories Ltd
Siemens Healthineers AG
Enzo Life Sciences, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.